Vaishali Pharma Ltd.
Snapshot View

41.75 -0.40 ▼-1.0%

23 July 2021, 03:58:57 P.M.
Volume: 32,055

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.vaishalipharma.com
Financial Indicators
Market Cap 44.03 Cr.
Earnings per share (EPS) 0.99 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 42.13 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 21.26 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.96 Calculated using Price: 41.75
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.05 Cr. 10,546,213 Shares
FaceValue 10
Company Profile

The company was incorporated on April 25, 2008 under the provisions of the Companies Act, 1956 as ‘Vaishali Pharma Private Limited’ at Mumbai, Maharashtra. The company acquired the business of M/s. Vaishali Pharmachem which was the proprietorship concern of its Promoter Atul Vasani vide Business Assignment Agreement dated July 01, 2008. It started with trading and marketing of APIs and further in the year 2012, it ventured into marketing of pharmaceuticals formulations, the manufacturing of which is outsourced by it to third parties. The company was converted into Public Company in the year 2017 and the name of the company was changed to ‘Vaishali Pharma Limited’. The company’s registered office is situated at Mumbai and warehousing facilities of the company is located at Bhiwandi, Maharashtra and Vapi, Gujarat.

The company has obtained ISO 9001:2015 Certification for the Quality Management System from Deutsche Accreditation Board, Germany and ISC Global, Dubai, UAE. It is also certified by European Certification Organisation and Compliance Certificate with regards to Council Directive 93/42/EEC as amended 2007/47/EC relating to Surgical Instruments & Medical Devices Directive. It has received Credit Rating Certification from NSIC CRLS1L for the year 2017-18 as well. The company has also been recognized by Government of India as a ‘One Star Export House’ and holds a valid certificate for the same from the Director General of Foreign Trade.

Business area of the company

The company is a pharmaceutical company, dealing in pharmaceutical formulations, APIs, surgical products, veterinary supplements. It is operating both in domestic and export markets. In domestic markets, it is majorly into trading of APIs whereas in export markets, it is into trading and marketing of APIs, formulations, surgical products and others. For its export markets, the company gets the formulations manufactured by third parties whose facilities are approved and certified by the respective countries for developing the respective products. At present, it has applied for 186 registrations in 13 countries for some of its products, out of which it has successfully received 71 approvals from 7 countries and is in process of obtaining remaining approvals, which will give boost to its export business operations.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.95%
1 Week
-0.71%
1 Month
-8.34%
3 Month
+3.34%
6 Month
-13.38%
1 Year
-7.12%
2 Year
+82.00%
5 Year
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 23.83 26.24 10.28 5.12 -0.94 19.80 6.49 3.40 0.15
Return on Capital Employed (%) 3.95 13.59 19.23 14.04 12.80 16.18 12.75 9.80 6.89
Return on Assets (%) 1.08 1.44 0.59 0.33 -0.06 1.51 1.47 1.08 0.05

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 2 3 3 3 3 4 21 21 21
Non Curr. Liab. 3 3 3 8 5 3 3 5 4
Curr. Liab. 30 43 47 34 42 37 41 42 40
Minority Int.
Equity & Liab. 35 49 53 46 49 45 64 69 66
Non Curr. Assets 1 1 2 2 2 5 5 6 5
Curr. Assets 34 48 52 44 47 40 59 63 61
Misc. Exp. not W/O
Total Assets 35 49 53 46 49 45 64 69 66

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 82 119 121 95 67 64 68 75 60
Other Income 0 1 4 3 1 2 2 2
Total Income 82 119 122 99 70 65 69 77 62
Total Expenditure -81 -117 -118 -95 -66 -61 -65 -73 -59
PBIDT 1 2 3 4 4 4 4 4 3
Interest -1 -3 -3 -3 -3 -3 -3 -3
Depreciation 0 0 0 0 0 0 0 0
Taxation 0 0 0 0 0 0 -1 0 0
Exceptional Items
PAT 0 1 0 0 0 1 1 1 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 4 -7 -4 5 0 -9 4 3
Cash Fr. Inv. 0 0 2 3 1 1 0 0
Cash Fr. Finan. -4 6 2 -8 -1 9 -4 -3
Net Change 0 -1 0 0 0 0 0
Cash & Cash Eqvt 2 1 1 1 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2018-03 (%) 2018-09 (%) 2019-03 (%) 2019-09 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%)
Promoter 70.02 70.02 70.02 56.37 64.03 64.03 63.88 63.84 63.81
Public 29.98 29.97 29.97 43.63 35.98 35.98 36.13 36.16 36.19
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Copy of Newspaper Publication
Vaishali Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Fri, 16 Jul 2021
Reply to Clarification Sought
VAISHALI: The Exchange had sought clarification from Vaishali Pharma Limited with respect to announcement dated 10-Jul-2021, regarding Appointment of Mr Pratik Vikram Jakhelia. On basis of above the Company was required to provide confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018. The response of the Company is attached.
Thu, 15 Jul 2021
Copy of Newspaper Publication
Vaishali Pharma Limited has informed the Exchange about Copy of Newspaper Publication

Technical Scans View Details

Fri, 23 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index
Close Crossing 20 EMA From Above Close Crossing 20 EMA From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%